Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 242
Filtrar
1.
BMC Pediatr ; 24(1): 571, 2024 Sep 07.
Artículo en Inglés | MEDLINE | ID: mdl-39244525

RESUMEN

OBJECTIVES: This study aimed to compare plasma concentrations of anesthetic drugs administered during Cesarean section with low Apgar score in neonates deliveried under general anesthesia and analyze associated risk factors. METHODS: Data from 76 neonates undergoing Cesarean section under general anesthesia with blood concentrations of anesthetic drugs were analyzed. A low Apgar score was defined as ≤ 7. Perioperative maternal and neonatal data were collected and analyzed. Neonates were divided into a control group (Group CON, n = 65) and a low Apgar score group (Group LAS, n = 11) based on Apgar score. RESULTS: There were no significant differences in the plasma concentrations of anesthetic drugs in maternal artery, umbilical vein or umbilical artery blood between the two groups. Risk factors for neonatal low Apgar scores during Cesarean section under general anesthesia were premature delivery (aOR 10.2, 95% CI = 1.8-56.9) and preoperative fetal distress (aOR 9.6, 95% CI = 1.3-69.0). The prediction model was: probability = 1/(e­Y), Y= -4.607 + 2.318× (premature delivery) + 2.261× (fetal distress) (yes = 1, no = 0). The Hosmer-Lemeshow test showed χ²= 9.587, P = 0.213, and the area under the curve (AUC) was 0.850 (0.670 ~ 1.000). With a cutoff value of 0.695, sensitivity and specificity were 81.8% and 87.7%, respectively. CONCLUSIONS: There was no correlation between blood concentration of general anesthetic drugs and Apgar score or occurrence of neonatal low Apgar scores. Premature delivery and preoperative fetal distress were identified as independent risk factors for neonatal low Apgar scores after Cesarean section under general anesthesia.


Asunto(s)
Anestesia General , Puntaje de Apgar , Cesárea , Humanos , Recién Nacido , Anestesia General/efectos adversos , Femenino , Embarazo , Factores de Riesgo , Adulto , Anestesia Obstétrica/métodos , Anestesia Obstétrica/efectos adversos , Masculino , Sufrimiento Fetal/sangre , Estudios Retrospectivos , Anestésicos/sangre , Anestésicos/efectos adversos , Nacimiento Prematuro
2.
J Pharmacol Exp Ther ; 380(2): 104-113, 2022 02.
Artículo en Inglés | MEDLINE | ID: mdl-34862270

RESUMEN

Allopregnanolone (ALLO) is a neurosteroid that modulates synaptic and extrasynaptic GABAA receptors. We hypothesize that ALLO may be useful as first-line treatment of status epilepticus (SE). Our objectives were to (1) characterize ALLO pharmacokinetics-pharmacodynamics PK-PD after intravenous (IV) and intramuscular (IM) administration and (2) compare IV and IM ALLO safety and tolerability. Three healthy dogs and two with a history of epilepsy were used. Single ALLO IV doses ranging from 1-6 mg/kg were infused over 5 minutes or injected IM. Blood samples, vital signs, and sedation assessment were collected up to 8 hours postdose. Intracranial EEG (iEEG) was continuously recorded in one dog. IV ALLO exhibited dose-proportional increases in exposure, which were associated with an increase in absolute power spectral density in all iEEG frequency bands. This relationship was best described by an indirect link PK-PD model where concentration-response was described by a sigmoidal maximum response (Emax) equation. Adverse events included site injection pain with higher IM volumes and ataxia and sedation associated with higher doses. IM administration exhibited incomplete absorption and volume-dependent bioavailability. Robust iEEG changes after IM administration were not observed. Based on PK-PD simulations, a 2 mg/kg dose infused over 5 minutes is predicted to achieve plasma concentrations above the EC50, but below those associated with heavy sedation. This study demonstrates that ALLO is safe and well tolerated when administered at 1-4 mg/kg IV and up to 2 mg/kg IM. The rapid onset of effect after IV infusion suggests that ALLO may be useful in the early treatment of SE. SIGNIFICANCE STATEMENT: The characterization of the pharmacokinetics and pharmacodynamics of allopregnanolone is essential in order to design clinical studies evaluating its effectiveness as an early treatment for status epilepticus in dogs and people. This study has proposed a target dose/therapeutic range for a clinical trial in canine status epilepticus.


Asunto(s)
Anestésicos/uso terapéutico , Anticonvulsivantes/uso terapéutico , Pregnanolona/uso terapéutico , Estado Epiléptico/tratamiento farmacológico , Anestésicos/administración & dosificación , Anestésicos/efectos adversos , Anestésicos/sangre , Animales , Anticonvulsivantes/administración & dosificación , Anticonvulsivantes/efectos adversos , Anticonvulsivantes/sangre , Perros , Relación Dosis-Respuesta a Droga , Electroencefalografía , Inyecciones Intramusculares , Inyecciones Intravenosas , Pregnanolona/administración & dosificación , Pregnanolona/efectos adversos , Pregnanolona/sangre , Estado Epiléptico/veterinaria
3.
Forensic Sci Int ; 325: 110889, 2021 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-34225211

RESUMEN

Medication-induced prolongation of the QT-interval (miQTP) can lead to cardiac arrhythmia. Our aim was to investigate the prevalence of forensic autopsy cases where fatal cardiac arrhythmia related to treatment with QT-prolonging medications (QT-PMs) could be suspected. We performed a cross-sectional study of 741 forensic autopsies undertaken at our institution in non-drug addicts aged 15 years or above from 2017 to 2019. We defined a high risk of miQTP by one detected QT-PM in a concentration above therapeutic level, or two or more detected QT-PMs in post mortem blood. We reviewed the autopsy reports from cases with a high miQTP-risk to identify cases with no other apparent cause of death. We discarded suicides and cases with lethal levels of QT-PMs. We identified 167 cases (22.5%) with high risk of miQTP, and discarded 36 suicides (4.9%) and 7 (0.9%) with lethal levels of QT-PMs. Apart from a high risk of miQTP, no other apparent explanation of the cause of death was present in seven (0.9%). In 18 cases (2.4%) with high miQTP-risk, the cause of death was primarily attributed to cardiac changes other than acute cardiovascular events. In conclusion, 22.5% had a high risk of miQTP, and fatal cardiac arrhythmia related to treatment with QT-PMs could be suspected in 0.9%. However, a genetic pro-arrhythmic background could not be excluded in our study. Furthermore, it is possible that QT-PMs could have played a role in some of the 2.4% of cases where the cause of death was mainly attributed to cardiac changes and the risk of miQTP was high.


Asunto(s)
Arritmias Cardíacas/inducido químicamente , Adulto , Anciano , Analgésicos Opioides/efectos adversos , Analgésicos Opioides/sangre , Anestésicos/efectos adversos , Anestésicos/sangre , Antidepresivos/efectos adversos , Antidepresivos/sangre , Antieméticos/efectos adversos , Antieméticos/sangre , Antipsicóticos/efectos adversos , Antipsicóticos/sangre , Autopsia , Estudios Transversales , Dinamarca , Diuréticos/efectos adversos , Diuréticos/sangre , Femenino , Antagonistas de los Receptores Histamínicos/efectos adversos , Antagonistas de los Receptores Histamínicos/sangre , Humanos , Masculino , Persona de Mediana Edad
4.
Talanta ; 210: 120652, 2020 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-31987200

RESUMEN

Here, the novel petal-shaped ionic liquids modified covalent organic frameworks (PS-IL-COFs) particles have been synthesized by using ionic liquids as modifying agent, which could be beneficial to avoid the aggregation of COFs during the preparation and improve its dispersing performance. The novel PS-IL-COFs particles have been used and evaluated in the one step cleanup and extraction (OSCE) procedure for human plasma prior to the analysis of 3 general anesthetics by liquid chromatography-tandem quadrupole mass spectrometry (LC-MS/MS). In the OSCE procedure, human plasma samples are directly mixed with extraction solvent and PS-IL-COFs particles, and the extraction and cleanup procedure have been carried out simultaneously. Compared with the Oasis PRiME HLB cartridge method, the OSCE procedure using PS-IL-COFs particles as sorbents is much more effective for the minimization of ion suppression resulted from blood phospholipids. Under optimal conditions, the PS-IL-COFs particles show higher cleanup efficiency of 3 general anesthetics with recoveries in the range of 82.5%-115%. The limits of quantification (LOQs) for propofol, ketamine and etomidate are 0.18 µg/L, 0.15 µg/L and 0.016 µg/L, respectively. Validation results on linearity, specificity, precision and trueness, as well as on the application to analysis of general anesthetics in a case of a 54-year-old female suffered gallstone demonstrate the applicability to clinical studies.


Asunto(s)
Anestésicos/sangre , Etomidato/sangre , Líquidos Iónicos/química , Ketamina/sangre , Compuestos Orgánicos/química , Propofol/sangre , Cromatografía Líquida de Alta Presión , Femenino , Humanos , Persona de Mediana Edad , Tamaño de la Partícula , Propiedades de Superficie , Espectrometría de Masas en Tándem
5.
Anesth Analg ; 130(3): 704-714, 2020 03.
Artículo en Inglés | MEDLINE | ID: mdl-31124836

RESUMEN

BACKGROUND: Previous formulations of alfaxalone have shown it to be a fast-acting intravenous anesthetic with high therapeutic index. Alfaxalone has been reformulated for human use as Phaxan, an aqueous solution of 10 mg/mL of alfaxalone and 13% betadex. This study assessed the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of alfaxalone given as a bolus intravenous injection of this formulation to human male volunteers. METHODS: A dose of 0.5 mg/kg (0.42-0.55 mg/kg) of alfaxalone [mean (range)] was given by single intravenous bolus injection to 12 healthy subjects. Plasma alfaxalone concentrations and bispectral index (BIS) values were analyzed using an integrated pharmacokinetic-pharmacodynamic (PKPD) model using nonlinear mixed-effects models. Effect (BIS) was described using a sigmoidal fractional maximum effect (EMAX) model. All parameters were scaled using allometry and standardized to a 70-kg person using exponents of 0.75 for clearance parameters (CL, Q2, and Q3), 1.0 for volumes (V1, V2, and V3), and 0.25 for time-related parameters half-time keo (t1/2keo). RESULTS: A 3-compartment model used to fit PK data with an additional compartment, linked by t1/2keo to describe the effect compartment, yielded alfaxalone PK parameter estimates: CL: 1.08 L/min; 0.87-1.34 L/min (median; 95% confidence interval [CI]); central volume of distribution (V1): 0.99 L; 0.53-2.05 L (median; 95% CI); intercompartment CLs (Q2): 0.87 L/min; 0.32-1.71 L/min (median; 95% CI) and Q3: 0.46 L/min; 0.19-1.03 L/min (median; 95% CI); and peripheral volumes of distribution (V2): 6.36 L; 2.79-10.7 L (median; 95% CI) and V3: 19.1 L; 8.61-37.4 L (median; 95% CI). PD interrogation assumed a baseline BIS of 96, with an estimated EMAX: 0.94; 0.71-0.99 (median; 95% CI), a plasma concentration (Cp) for 50% effect (C50): 0.98 mg/L; 0.83-1.09 mg/L (median; 95% CI), and a Hill coefficient (γ): 12.1; 6.7-15 (median; 95% CI). The t1/2keo was 8 minutes; 4.70-12.8 minutes (median; 95% CI). The mean time to a BIS 50 was 0.94 minutes (standard deviation [SD] = 0.2 minutes). CONCLUSIONS: After a single bolus intravenous injection, alfaxalone has a high plasma CL equal to hepatic blood flow as reported for earlier studies of bolus injections of a previous formulation of alfaxalone. The plasma levels associated with BIS values of <60 are comparable to those previously reported in patients anesthetized with alfaxalone. The t1/2keo is relatively high, but the large Hill coefficient contributes to rapid onset and offset of action. This information can inform future studies of this formulation.


Asunto(s)
Anestésicos/administración & dosificación , Anestésicos/farmacocinética , Estado de Conciencia/efectos de los fármacos , Pregnanodionas/administración & dosificación , Pregnanodionas/farmacocinética , Adolescente , Adulto , Anestésicos/sangre , Monitores de Conciencia , Composición de Medicamentos , Semivida , Voluntarios Sanos , Humanos , Inyecciones Intravenosas , Masculino , Tasa de Depuración Metabólica , Modelos Biológicos , Nueva Zelanda , Pregnanodionas/sangre , Adulto Joven
7.
Arq. bras. med. vet. zootec. (Online) ; 71(5): 1558-1564, set.-out. 2019. tab
Artículo en Inglés | VETINDEX, LILACS | ID: biblio-1038680

RESUMEN

The aim of this study was to assess the effects of chemical restraint, general anesthesia and opioid treatment on hematological components in Cuniculus paca. Eight healthy, adult, captivity female animals , underwent three laparoscopic procedures with a 15-day interval were evaluated. After physical restraint, an association of ketamine (25mg/kg) and midazolam (0.5mg/kg) was administered intramuscularly for chemical restraint. Posteriorly, anesthesia was induced and maintained with isoflurane; and randomly administered methadone (0.5mg/kg), tramadol (5mg/kg) or saline-placebo (0,1mL/kg) intramuscularly. After pharmacological restraint and in the final laparoscopy stage, venous blood samples were obtained for complete blood count, total plasma protein (TP), creatinine, alanine aminotransferase (ALT), sodium, potassium, chloride and ionized calcium analysis. During general anesthesia, hemoglobin, TP concentration and lymphocytes decreased (P=0.029; <0.001; 0.022 respectively), whereas the potassium levels increased (P=0.034). In conclusion, chemical restraint with ketamine/midazolam association causes a slight decrease in blood cellular components. Isoflurane anesthesia for laparoscopic procedure lead to decrease in hemoglobin, lymphocytes and protein concentrations, while potassium increased, without any influence from the tramadol or methadone treatment. However, these alterations were transient, and its hematologic values can collaborate in carrying out epidemiological, pathophysiological or case studies in the Cuniculus paca.(AU)


O objetivo do presente estudo foi avaliar os efeitos de contenção química, anestesia geral e tratamento com opiáceos nos parâmetros hematológicos em Cuniculus paca. Foram avaliados oito animais saudáveis, fêmeas, adultas, de cativeiro, que foram submetidas a três procedimentos laparoscópicos, com intervalo de 15 dias. Após a contenção física, uma associação de cetamina (25mg/kg) e midazolam (0,5mg/kg) foi administrada por via intramuscular para contenção química. Posteriormente, a anestesia foi induzida e mantida com isoflurano, e administrou-se aleatoriamente metadona (0,5mg/kg), tramadol (5mg/kg) ou placebo salina por via intramuscular. Após a contenção farmacológica e em estágio final da laparoscopia, foram obtidas amostras de sangue venoso para contagem sanguínea completa, proteína de plasma total (TP), creatinina, alanina aminotransferase (ALT), cálcio, sódio, potássio e cloreto ionizado. Durante a anestesia geral, a concentração de hemoglobina, TP e linfócitos diminuiu (P= 0,029;< 0,001; 0,022, respectivamente), enquanto os níveis de potássio aumentaram (P= 0,034). Em conclusão, a contenção química com associação de cetamina/midazolam promove uma ligeira diminuição dos componentes celulares do sangue. A anestesia com isoflavano para o procedimento laparoscópico levou a uma diminuição das concentrações de hemoglobina, linfócitos e proteínas, enquanto o potássio aumentou, sem qualquer influência do tratamento com tramadol ou metadona. No entanto, essas alterações foram transitórias, e os seus valores hematológicos obtidos podem colaborar na realização de estudos epidemiológicos, fisiopatológicos ou casuísticas para Cuniculus paca.(AU)


Asunto(s)
Animales , Femenino , Cuniculidae/cirugía , Cuniculidae/sangre , Anestesia/veterinaria , Anestésicos/sangre , Tramadol/administración & dosificación , Midazolam/administración & dosificación , Isoflurano/administración & dosificación , Ketamina/administración & dosificación , Metadona/administración & dosificación
8.
J Vet Pharmacol Ther ; 42(6): 713-721, 2019 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-31435964

RESUMEN

Pharmacokinetics and pharmacodynamics of alfaxalone was performed in mallard ducks (Anas platyrhynchos) after single bolus injections of 10 mg/kg administered intramuscularly (IM; n = 10) or intravenously (IV; n = 10), in a randomized cross-over design with a washout period between doses. Mean (±SD) Cmax following IM injection was 1.6 (±0.8) µg/ml with Tmax at 15.0 (±10.5) min. Area under the curve (AUC) was 84.66 and 104.58 min*mg/ml following IV and IM administration, respectively. Volume of distribution (VD ) after IV dose was 3.0 L/kg. The mean plasma clearance after 10 mg/kg IV was 139.5 (±67.9) ml min-1  kg-1 . Elimination half-lives (mean [±SD]) were 15.0 and 16.1 (±3.0) min following IV and IM administration, respectively. Mean bioavailability at 10 mg/kg IM was 108.6%. None of the ducks achieved a sufficient anesthetic depth for invasive procedures, such as surgery, to be performed. Heart and respiratory rates measured after administration remained stable, but many ducks were hyperexcitable during recovery. Based on sedation levels and duration, alfaxalone administered at dosages of 10 mg/kg IV or IM in mallard ducks does not induce clinically acceptable anesthesia.


Asunto(s)
Anestésicos/farmacocinética , Patos/sangre , Pregnanodionas/farmacocinética , Anestésicos/administración & dosificación , Anestésicos/sangre , Animales , Área Bajo la Curva , Femenino , Semivida , Inyecciones Intramusculares , Inyecciones Intravenosas , Masculino , Pregnanodionas/administración & dosificación , Pregnanodionas/sangre
9.
J Sep Sci ; 42(11): 2062-2068, 2019 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-30938060

RESUMEN

A method of capillary electrophoresis with contactless conductivity detection has been developed for non-enantioselective monitoring the anaesthetic ketamine and its main metabolite norketamine. The separation is performed in a 15 µm capillary with an overall length of 31.5 cm and length to detector of 18 cm; inner surface of the capillary is covered with a commercial coating solution to reduce the electroosmotic flow. In an optimised background electrolyte with composition 2 M acetic acid + 1% v/v coating solution under application of a high voltage of 30 kV, the migration time is 97.1 s for ketamine and 95.8 s for norketamine, with an electrophoretic resolution of 1.2. The attained detection limit was 83 ng/mL (0.3 µmol/L) for ketamine and 75 ng/mL (0.3 µmol/L) for norketamine; the number of theoretic plates for separation of an equimolar model mixture with a concentration of 2 µg/mL was 683 500 plates/m for ketamine and 695 400 plates/m for norketamine. Laboratory preparation of rat blood plasma is based on mixing 10 µL of plasma with 30 µL of acidified acetonitrile, followed by centrifugation. A pharmacokinetic study demonstrated an exponential decrease in the plasma concentration of ketamine after intravenous application and much slower kinetics for intraperitoneal application.


Asunto(s)
Anestésicos/sangre , Ketamina/análogos & derivados , Ketamina/sangre , Anestésicos/farmacocinética , Animales , Conductividad Eléctrica , Ketamina/metabolismo , Ketamina/farmacocinética , Límite de Detección , Masculino , Ratas , Ratas Wistar
10.
A A Pract ; 13(3): 96-98, 2019 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-30920426

RESUMEN

Intravenous lidocaine is increasingly being utilized as an opioid-sparing analgesic. A 55-year-old man with well-controlled human immunodeficiency virus on highly active antiretroviral therapy was prescribed a lidocaine infusion at 1 mg/kg/h for postoperative pain. On postoperative day 2, the patient experienced 4 unresponsive episodes with tachycardia, hypertension, and oxygen desaturation. Serum lidocaine level was available 2 days later (high 6.3 µg/mL, therapeutic range 2.5-3.5 µg/mL). There is significant pharmacokinetic interaction between lidocaine and this patient's human immunodeficiency virus medications. This case highlights the need for a readily accessible list of medications that caution against lidocaine. We propose in-house serum lidocaine levels to monitor patients at an increased risk for toxicity.


Asunto(s)
Anestésicos/efectos adversos , Lidocaína/efectos adversos , Dolor Postoperatorio/tratamiento farmacológico , Anestésicos/sangre , Anestésicos/farmacocinética , Fármacos Anti-VIH/farmacocinética , Fármacos Anti-VIH/uso terapéutico , Terapia Antirretroviral Altamente Activa , Infecciones por VIH/tratamiento farmacológico , Humanos , Infusiones Intravenosas , Lidocaína/sangre , Lidocaína/farmacocinética , Masculino , Persona de Mediana Edad , Periodo Perioperatorio
11.
J Am Anim Hosp Assoc ; 55(2): 70-77, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30776258

RESUMEN

The effects of intramuscular injection of alfaxalone ([ALF] 5 mg/kg), acepromazine ([ACE] 0.05 mg/kg), and an ALF-ACE combination ([AA] 0.025 mg/kg ACE followed by 2.5 mg/kg ALF) on the sedation, echocardiographic, biochemical, and blood gas indexes and recovery were evaluated in seven cats. No sedation was obtained with ACE, and sedation scores were higher with ALF than with AA treatment. Compared with baseline, an increase in heart rate occurred after ACE, and all treatments caused a decrease in systemic arterial pressure. Decreased left ventricular internal dimension in diastole, end-diastolic volume of the left ventricle, stroke volume, and left atrial dimension were identified after AA. There were minimal changes in echocardiographic variables after ALF. Biochemical and blood gas analysis showed no significant changes after all treatments. Although the difference in quality of recovery between the AA and ALF treatment groups was insignificant, all cats treated with AA or ALF showed ataxia. The AA combination did not change the recovery score, and tremor and twitching were identified more frequently with AA than ALF. ALF had no significant effects on echocardiographic, biochemical, or blood gas variables. ALF could be considered a useful sedative option for diagnostic procedures and echocardiography in cats.


Asunto(s)
Acepromazina/farmacología , Anestésicos/farmacología , Antagonistas de Dopamina/farmacología , Pregnanodionas/farmacología , Acepromazina/administración & dosificación , Acepromazina/sangre , Anestésicos/administración & dosificación , Anestésicos/sangre , Animales , Área Bajo la Curva , Análisis de los Gases de la Sangre/veterinaria , Presión Sanguínea/efectos de los fármacos , Gatos , Estudios Cruzados , Antagonistas de Dopamina/administración & dosificación , Antagonistas de Dopamina/sangre , Relación Dosis-Respuesta a Droga , Quimioterapia Combinada/veterinaria , Ecocardiografía/veterinaria , Frecuencia Cardíaca/efectos de los fármacos , Inyecciones Intramusculares/veterinaria , Pregnanodionas/administración & dosificación , Pregnanodionas/sangre , Distribución Aleatoria
13.
Bioorg Med Chem Lett ; 28(22): 3502-3505, 2018 12 01.
Artículo en Inglés | MEDLINE | ID: mdl-30318437

RESUMEN

The low water solubility of Propofol resulted in complicated formulation and adverse effects during its clinical application. To improve its water solubility and maintain its anesthetic effects, Propofol prodrugs with monodisperse oligoethylene glycols as solubility enhancer were designed and synthesized. Monodisperse oligoethylene glycols enable the concise manipulation of water solubility, biocompatibility and anesthetic effects. Through the physicochemical and biological assay, a few water soluble prodrugs of Propofol were identified as promising anesthetic to overcome the drawbacks associated with Propofol.


Asunto(s)
Anestésicos/química , Polietilenglicoles/química , Profármacos/química , Propofol/química , Anestésicos/sangre , Anestésicos/farmacología , Animales , Línea Celular , Supervivencia Celular/efectos de los fármacos , Humanos , Profármacos/síntesis química , Profármacos/farmacología , Propofol/sangre , Propofol/farmacología , Ratas , Ratas Sprague-Dawley , Solubilidad
14.
IEEE Trans Biomed Circuits Syst ; 12(5): 1056-1064, 2018 10.
Artículo en Inglés | MEDLINE | ID: mdl-30072339

RESUMEN

In this paper, we present the design, the implementation and the validation of a novel Internet of Things (IoT) drug monitoring system for the online continuous and simultaneous detection of two main anesthetics, e.g., propofol and paracetamol, in undiluted human serum. The described full system consists of a custom-built electronic Raspberry Pi (RPi) based Printed Circuit Board (PCB) that drives and reads out the signal from an electrochemical sensing platform integrated into a fluidic system. Thanks to the Polydimethylsiloxane (PDMS) fluidic device, the analyzed sample is automatically fluxed on the sensing site. The IoT network is supported by a Cloud system, which allows the doctor to control and share all the patient's data through a dedicated Android application and a smart watch. The validation closes with the first ever demonstration that our system successfully works for the simultaneous monitoring of propofol and paracetamol in undiluted human serum by measuring the concentration trends of these two drugs in fluxing conditions over time.


Asunto(s)
Anestésicos/sangre , Monitoreo de Drogas/métodos , Tecnología de Sensores Remotos/métodos , Nube Computacional , Dimetilpolisiloxanos/química , Monitoreo de Drogas/instrumentación , Técnicas Electroquímicas/métodos , Electrodos , Grafito/química , Humanos , Internet , Tecnología de Sensores Remotos/instrumentación
15.
J Neurosci Methods ; 305: 82-88, 2018 07 15.
Artículo en Inglés | MEDLINE | ID: mdl-29772269

RESUMEN

BACKGROUND: Different levels of consciousness are required in order to perform different medical procedures. Sedation scales established to objectively define various levels of sedation in humans have not been thoroughly characterized in non-human species. Postural changes in rats or dogs are useful as gross measures of sedation but are inadequate for quantitative assessment since graded levels of sedation are difficult to delineate and obscured by movement abnormalities. NEW METHOD: A new canine sedation scoring (CSS) method was developed based on the modified observer's assessment of alertness and sedation score (MOAA/S) used in humans. The method employed a combination of physical, auditory and somatosensory stimuli of increasing intensity. Cardiovascular, respiratory, and a neurophysiological measure of sedation (bispectral index: BIS) data were recorded. Validation studies were performed following intravenous loading and constant rate infusion of propofol or a novel synthetic neuroactive steroid (SGE-746). RESULTS: Four levels of consciousness were identified: 1) Awake, 2) Moderate Sedation (MS), 3) Deep Sedation (DS) and 4) General Anesthesia (GA). Cardiorespiratory measurements obtained after bolus administration of propofol and SGE-746 and at the end of each CRI remained within normal limits. Canine sedation scores correlated with BIS for SGE-746. SGE-746 exhibited a more gradual exposure-response relationship than propofol. Larger increases in the plasma concentration from awake values were required to achieve different levels of sedation with SGE-746 compared to propofol. COMPARISON WITH EXISTING METHODS: No other canine sedation scoring methods are widely accepted. CONCLUSION: A CSS method, based on the human MOAA/S scale defined four levels of consciousness in dogs and provided better resolution of sedation depth than BIS alone.


Asunto(s)
Anestésicos/farmacología , Sedación Consciente/métodos , Hipnóticos y Sedantes/farmacología , Propofol/farmacología , Esteroides/farmacología , Administración Intravenosa , Anestésicos/sangre , Animales , Estado de Conciencia/efectos de los fármacos , Estado de Conciencia/fisiología , Perros , Relación Dosis-Respuesta a Droga , Hipnóticos y Sedantes/sangre , Masculino , Proyectos Piloto , Propofol/sangre , Esteroides/sangre
16.
N Z Vet J ; 66(4): 172-177, 2018 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-29562829

RESUMEN

AIMS: To determine the pharmacokinetics, and anaesthetic and sedative effects of alfaxalone after I/V and I/M administration to cats. METHODS: Six European shorthair cats, three males and three females, with a mean weight of 4.21 (SD 0.53) kg and aged 3.8 (SD 0.9) years were enrolled in this crossover, two-treatment, two-period study. Alfaxalone at a dose of 5 mg/kg was administered either I/V or I/M. Blood samples were collected between 2-480 minutes after drug administration and analysed for concentrations of alfaxalone by HPLC. The plasma concentration-time curves were analysed by non-compartmental analysis. Sedation scores were evaluated between 5-120 minutes after drug administration using a numerical rating scale (from 0-18). Intervals from drug administration to sit, sternal and lateral recumbency during the induction phase, and to head-lift, sternal recumbency and standing position during recovery were recorded. RESULTS: The mean half-life and mean residence time of alfaxalone were longer after I/M (1.28 (SD 0.21) and 2.09 (SD 0.36) hours, respectively) than after I/V (0.49 (SD 0.07) and 0.66 (SD 0.16) hours, respectively) administration (p<0.05). Bioavailability after I/M injection of alfaxalone was 94.7 (SD 19.8)%. The mean intervals to sternal and lateral recumbency were longer in the I/M (3.73 (SD 1.99) and 6.12 (SD 0.90) minutes, respectively) compared to I/V (0 minutes for all animals) treated cats (p<0.01). Sedation scores indicative of general anaesthesia (scores >15) were recorded from 5-15 minutes after I/V administration and deep sedation (scores 11-15) at 20 and 30 minutes. Deep sedation was observed from 10-45 minutes after I/M administration. One cat from each group showed hyperkinesia during recovery, and the remainder had an uneventful recovery. CONCLUSIONS AND CLINICAL RELEVANCE: Alfaxalone administered I/V in cats provides rapid and smooth induction of anaesthesia. After I/M administration, a longer exposure to the drug and an extended half life were obtained compared to I/V administration. Therefore I/M administration of alfaxalone could be a reliable, suitable and easy route in cats, taking into account that alfaxalone has a slower onset of sedation than when given I/V and achieves deep sedation rather than general anaesthesia.


Asunto(s)
Anestésicos/farmacocinética , Gatos/fisiología , Pregnanodionas/farmacocinética , Administración Intravenosa/veterinaria , Análisis de Varianza , Periodo de Recuperación de la Anestesia , Anestésicos/administración & dosificación , Anestésicos/sangre , Anestésicos/farmacología , Anestésicos por Inhalación , Animales , Área Bajo la Curva , Disponibilidad Biológica , Gatos/metabolismo , Cromatografía Líquida de Alta Presión/veterinaria , Estudios Cruzados , Sedación Profunda/veterinaria , Femenino , Semivida , Hipercinesia/inducido químicamente , Hipercinesia/veterinaria , Inyecciones Intramusculares/veterinaria , Masculino , Éteres Metílicos , Pregnanodionas/administración & dosificación , Pregnanodionas/sangre , Pregnanodionas/farmacología , Estudios Prospectivos , Reproducibilidad de los Resultados , Sevoflurano , Factores de Tiempo
17.
Vet Anaesth Analg ; 45(3): 269-277, 2018 May.
Artículo en Inglés | MEDLINE | ID: mdl-29415861

RESUMEN

OBJECTIVE: To determine the effective plasma alfaxalone concentration for the production of immobility in cats. STUDY DESIGN: Prospective up-and-down study. ANIMALS: Sixteen 1-2 year old male castrated research cats. METHODS: Cats were instrumented with catheters in a jugular and a medial saphenous vein. Alfaxalone was administered via the medial saphenous catheter, using a target-controlled infusion system. The infusion lasted for approximately 32 minutes. A noxious stimulus (tail clamp) was applied 30 minutes after starting the alfaxalone infusion, until the cat moved or 60 seconds had elapsed, whichever occurred first. The target alfaxalone concentration was set at 5 mg L-1 in the first cat and increased or decreased by 1 mg L-1 in subsequent cats, if the previous cat had moved or not moved in response to stimulation, respectively. This was continued until six independent crossovers (different responses in pairs of subsequent cats) had been observed. Blood samples were collected before alfaxalone administration, and 15 and 31 minutes after starting the administration, for the determination of plasma alfaxalone concentration using liquid chromatography/tandem mass spectrometry. The alfaxalone concentration yielding a probability of immobility in 50% (EC50), 95% (EC95) and 99% (EC99) of the population, and their respective 95% Wald confidence intervals were calculated. RESULTS: The EC50, EC95 and EC99 for alfaxalone-induced immobility were 3.7 (2.4-4.9), 6.2 (4.7-) and 7.6 (5.5-) mg L-1, respectively. CONCLUSIONS AND CLINICAL RELEVANCE: The effective plasma alfaxalone concentration for immobility in cats was determined. This value will help in the design of pharmacokinetic-based dosing regimens.


Asunto(s)
Anestésicos/sangre , Inmovilización/veterinaria , Pregnanodionas/sangre , Anestésicos/administración & dosificación , Animales , Gatos , Inmovilización/métodos , Infusiones Intravenosas/veterinaria , Masculino , Pregnanodionas/administración & dosificación
18.
J Vet Med Sci ; 79(4): 801-806, 2017 Apr 20.
Artículo en Inglés | MEDLINE | ID: mdl-28302956

RESUMEN

Anesthetics utilized for the immobilization of pregnant mammals are prone to crossing the placental barrier and cause adverse effects to the fetuses. In this study, we develop a facile method employing high performance liquid chromatography (HPLC) for the study of Telazol crossing the placental barrier of pregnant pigs. The method mainly relies on the efficient extraction strategy that includes the mobile phase composed of 10 mM ammonium acetate aqueous solution-acetonitrile (1:4, v/v). When the injected dose of Telazol is 10 mg/kg (5 mg/kg of each constituent drug, zolazepem and tiletamine), zolazepam can cross the placental barrier as it is detected in both uterus and umbilical cord with approximately the same content. Conversely, tiletamine is detected in neither uterus nor umbilical cord, indicating the absence of placental transfer of tiletamine. The different absorption rates of the two dosage-equal compounds by pigs are found to be the main cause of their different abilities to cross the placental barrier.


Asunto(s)
Anestésicos/farmacocinética , Cromatografía Líquida de Alta Presión/veterinaria , Placenta/metabolismo , Porcinos/sangre , Tiletamina/farmacocinética , Zolazepam/farmacocinética , Anestésicos/sangre , Animales , Combinación de Medicamentos , Femenino , Embarazo , Tiletamina/sangre , Útero/metabolismo , Zolazepam/sangre
19.
J Chromatogr B Analyt Technol Biomed Life Sci ; 1036-1037: 42-49, 2016 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-27710889

RESUMEN

Neosaxitoxin, a member of the saxitoxin family of paralytic shellfish poisoning toxins, has shown potential as an effective, long-acting, anesthetic. We describe the development and validation of a highly sensitive method for measurement of neosaxitoxin in human plasma using liquid chromatography tandem mass spectrometry (LC-MS/MS) and provide evidence for its use in a human pharmacokinetic study. Samples were prepared using cation exchange solid phase extraction followed by hydrophilic interaction liquid chromatography and MS/MS detection in positive electrospray ionization mode. Multiple reaction monitoring was used to monitor neosaxitoxin (m/z 316.17>220.07) and the internal standard analogue decarbamoylneosaxitoxin (m/z 273.12>180.00). The method was validated for lower limit of quantification, precision, accuracy, linearity and matrix effect. The stability of neosaxitoxin in plasma matrix at various storage conditions was also investigated. Standard curves for calibration were linear (r>0.995) across the assay calibration range, 10 to 1000pg/mL. The analytical measurable range of the assay was 10-10,000pg/mL in plasma matrix. This method has demonstrated excellent sensitivity demonstrating a lower limit of quantification in human plasma of 10pg/mL. The mean, inter-batch variation was <5.2% across the concentration range 30 to 800pg/mL. This method was successfully used in a phase 1 trial to investigate the pharmacokinetic profile of neosaxitoxin in humans following the intravenous administration of the drug at a range of doses up to 40µg. We conclude that our high-sensitivity method for measurement of neosaxitoxin in human plasma is capable of supporting future clinical trials.


Asunto(s)
Anestésicos/sangre , Cromatografía Líquida de Alta Presión/métodos , Bloqueantes Neuromusculares/sangre , Saxitoxina/análogos & derivados , Espectrometría de Masas en Tándem/métodos , Adolescente , Adulto , Humanos , Límite de Detección , Masculino , Saxitoxina/sangre , Extracción en Fase Sólida/métodos , Adulto Joven
20.
Am J Vet Res ; 77(10): 1057-63, 2016 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-27668576

RESUMEN

OBJECTIVE To evaluate the effect of IM administration of a tiletamine hydrochloride-zolazepam hydrochloride (TZ) combination with either dexmedetomidine hydrochloride or saline (0.9% NaCl) solution (SS) on the motor response to claw clamping, selected cardiorespiratory variables, and quality of recovery from anesthesia in alpacas. ANIMALS 5 adult sexually intact male alpacas. PROCEDURES Each alpaca was given the TZ combination (2 mg/kg) with dexmedetomidine (5 [D5], 10 [D10], 15 [D15], or 20 [D20] µg/kg) or SS IM at 1-week intervals (5 experiments); motor response to claw clamping was assessed, and characteristics of anesthesia, recovery from anesthesia, and selected cardiorespiratory variables were recorded. RESULTS Mean ± SEM duration of lack of motor response to claw clamping was longest when alpacas received treatments D15 (30.9 ± 5.9 minutes) and D20 (40.8 ± 5.9 minutes). Duration of lateral recumbency was significantly longer with dexmedetomidine administration. The longest time (81.3 ± 10.4 minutes) to standing was observed when alpacas received treatment D20. Following treatment SS, 4 alpacas moved in response to claw clamping at the 5-minute time point. Heart rate decreased from pretreatment values in all alpacas when dexmedetomidine was administered. Treatments D10, D15, and D20 decreased Pao2, compared with treatment SS, during the first 15 minutes. During recovery, muscle stiffness and multiple efforts to regain a sternal position were observed in 3 SS-treated and 1 D5-treated alpacas; all other recoveries were graded as excellent. CONCLUSIONS AND CLINICAL RELEVANCE In TZ-anesthetized alpacas, dexmedetomidine (10, 15, and 20 µg/kg) administered IM increased the duration of lack of motor response to claw clamping, compared with the effect of SS.


Asunto(s)
Anestésicos/farmacocinética , Camélidos del Nuevo Mundo/metabolismo , Dexmedetomidina/farmacología , Frecuencia Cardíaca/efectos de los fármacos , Hipnóticos y Sedantes/farmacología , Tiletamina/farmacocinética , Zolazepam/farmacocinética , Anestesia/veterinaria , Anestésicos/administración & dosificación , Anestésicos/sangre , Animales , Dexmedetomidina/administración & dosificación , Relación Dosis-Respuesta a Droga , Combinación de Medicamentos , Hipnóticos y Sedantes/administración & dosificación , Inyecciones Intramusculares/veterinaria , Masculino , Recuperación de la Función , Tiletamina/administración & dosificación , Tiletamina/sangre , Zolazepam/administración & dosificación , Zolazepam/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA